cyrilzakka/clinical-trials huggingface dataset:
The Effect of Emotional Freedom Technique and Virtual Reality Glasses on Anxiety and Vital Signs

The aim of the study was to examine the effects of the emotional freedom technique and virtual reality glasses applied to individuals receiving hyperbaric oxygen therapy for the first time on anxiety and vital signs. The hypotheses of this research are that there is a difference between the emotional liberation technique and virtual reality glasses groups and the control group in terms of anxiety and vital signs.

This study was designed as a pretest-posttest regular parallel group, randomized controlled experimental. The research will be carried out in Konya City Hospital Hyperbaric Oxygen Therapy Unit. Patients will be randomly assigned to three groups: emotional freedom technique group (25), virtual reality glasses group (25) and control group (25). For Emotional Freedom Technique Group: The emotional freedom technique will be applied by the researcher who has received the practitioner training certificate. For Virtual Reality Glasses Group: The video containing the nature walk will be watched by virtual reality. For the Control Group: No intervention will be made in the control group. Standard care will be given. The primary result of this study is to determine the patients' anxiety scores. Secondary results of the research are to determine the patients' vital signs.

Eligibility Criteria:
İnclusion Criteria

* Applying HBO treatment for the first time,
* Volunteering to participate in the research,
* Those who are between the ages of 18 and 65,
* Able to speak and understand Turkish (patients who will not have communication problems),
* Without a psychiatric diagnosis,
* Those who have not received training on coping with anxiety and fear before,
* Those who have not attended a course on energy therapy before,
* Vital signs are within normal limits

Exclusion Criteria:

* Having hearing and vision problems,
* Urgently placed on HBO treatment,
* Patients without chronic diseases,
* Patients with impaired tissue integrity at EFT energy points
Gastric Residuals in Preterm Infants

Checking of gastric residuals prior to the continuation/increase of enteral feeding prolongs the time to establish full gastric feeding in the early postnatal period.


Eligibility Criteria:
Inclusion Criteria:

* Infants with a birth weight ≥ 1500g and \< 2000g
* Age ≤48 hours of life
* Informed, written parental consent

Exclusion Criteria:

* Antenatally recognized gastrointestinal malformation
* Major congenital anomaly
* Chromosomal anomaly
* NEC stage II
* Severe acidosis, asphyxia (pH \<7.0)
* Severe growth restriction below 3rd percentile
Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents

For this study, the investigators will be collecting data based on patients' random selection to two different approved standard of care treatments for ascites: Subjects will get randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or Group B: an early transjugular intrahepatic portosystemic shunt (TIPS) procedure.

End Stage Liver Disease (ESLD) severely impacts body function leading to elevated blood pressure within the liver called "portal hypertension." One of its subsequent symptoms is ascites, or fluid accumulation in the abdomen. One standard treatment to relieve ascites is large volume paracentesis (puncture of the abdomen to drain the fluid). Another standard treatment is the TIPS procedure, which involves creating a shunt (small passage allowing fluid movement) within the liver to relieve the increased blood pressure in the liver.

For this study, the investigators will be collecting data based on patients' random selection to two different approved standard of care treatments for ascites: Subjects will get randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or Group B: an early transjugular intrahepatic portosystemic shunt (TIPS) procedure.

The study will include about 68 patients (34 patients will be selected for Group A: continuing conservative treatment of LVP with albumin infusion, and 34 patients will be selected for Group B: undergoing early TIPS with Gore®Viatorr®CX). Each patient will be followed up at 1 month, 3 months, 6 months, and 12 months.

The primary objective of this study is to evaluate the overall clinical efficacy in symptom relief of ascites of patients receiving the Gore® Viatorr® CX in early TIPS procedures compared to LVP (large volume paracenthesis). In order to so, the investigators will be using information found in patient medical records, collected as a part of standard of care, to analyze clinical outcomes, complications, and the rate of secondary interventions at follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Males and females \> 18 years of age at time of procedure
* First de novo TIPS placement
* Patent internal or external jugular vein
* Willing to provide the hepatology service information for follow up
* No known diagnosis of hypercoagulopathy
* No portal vein thrombosis
* No malignancy (must be a definite diagnosis)
* Patient must provide written informed consent
* Proper clinical indication of TIPS based on American Association for the Study of Liver Diseases (AASLD) guidelines

  * Recurrent ascites necessitating at least 2 large volume paracenteses performed within a minimum interval of 3 weeks

Exclusion Criteria:

* Age \<18
* LVP \> 6 times in 2 months
* Liver failure (Child Pugh \> 12)
* Cardiac failure
* No right jugular venous access
* Absolute TIPS contraindications (e.g. right heart failure, severe encephalopathy, liver failure, pregnant (if possible)).
Anterior Resin Bonded Restorations for Adolescent

a 24 Patients above 12 years old with missing upper incisor were divided into two groups, group 1: 12 patient will be treated by resin bonded bridge (RBB) with no preparation protocol, group 2: 12 patient will be treated by resin bonded bridge (RBB) with minimal preparation protocol.

(RBB) retention/survival, patient's speech as well as thermal sensitivity and patient's satisfaction will be evaluated for 12 month at 3,6,9 and 12 month.


Eligibility Criteria:
Inclusion Criteria:

1. 12-18 years old
2. Full set of permanent teeth.
3. Missing upper incisor
4. Controlled dental disease - no active caries or periodontal diseases
5. Patients will be available to be clinically reviewed up to 1 year

Exclusion Criteria:

1. Patients with uncontrolled active tooth decay or periodontal disease (i.e. 4+ mm probing depth and bleeding on probing).
2. Patients with teeth missing opposite to the planned RBB
3. Abutment tooth mobility of 2 or greater (Millers classification)
4. Patients with debilitating illnesses or complicating medical conditions
5. Heavily restored tooth abutment not suitable for an RBB
RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine

Evaluation of inhibiting rTMS QP over the visual cortex for the prevention of chronic migraine. The aim of the study is to confirm that inhibiting rTMS QP is capable to decrease the frequency of migraine and if its effect is stronger than placebo effect.

The investigators have already inquired if inhibiting rTMS QP over the visual cortex determines a reduction of frequency of migraine in a previous study. After 2 weekly sessions for a month, the investigators demonstrated a reduction of 47% in migraine frequency. In this study, the investigators aim to compare rTMS QP effect with the placebo effect and to evaluate if rTMS QP is capable to induce changes in VEP, CHEPS and QST.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of chronic migraine (ICHD III beta 1.3) with or without medication overuse.

Exclusion Criteria:

* other diseases or contraindication for the magnetic stimulation (epilepsy, pacemaker, metallic prothesis)
SCAN Memory Program Evaluation Study

The SCAN Memory Program Evaluation study is an evaluation of a randomized controlled trial intervention consisting of a care management program for cognitively-impaired health plan members and for their informal/family caregivers. The program includes collaboration between the health plan, partnering medical groups, and community organizations.

Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution. ACCESS, the prototype for the SCAN Memory Program, was developed and tested in San Diego County and was very successful in helping affected patients and their caregivers.


Eligibility Criteria:
Inclusion Criteria: Health plan member eligibility includes having a visit-based ICD-9 diagnostic code for dementia or a dementia-specific medication (including donepezil, rivastigmine, galantamine, and memantine) within administrative data any time prior to data inquiry for potential subjects. The health plan member must have a caregiver who can communicate by telephone and though that person might also be a health plan member, health plan membership for caregivers is not required. All subjects must be living in the community and if in a nursing facility, this must be for rehabilitation or respite care but not for long term care. Caregivers must be able to communicate in English or Spanish.

Exclusion Criteria: Person with dementia whose potential participation is declined by their physician. Those who do not have a family or informal caregiver cannot participate and caregivers who do no have telephone access or the capacity to consent to research evaluation are excluded. Patients who reside in nursing facilities as permanent residents are not eligible.

-
Effect of Rifampin on Bosutinib When Both Are Given to Healthy People

Study to examine whether rifampin has an effect on the pharmacokinetics of bosutinib.


Eligibility Criteria:
Inclusion Criteria:

* Healthy men age 18-50
* Healthy women of nonchildbearing potential, age 18-50
Determinants of Health Status and Quality of Life in Patients With Primary Immunodeficiencies Inhereted Diagnosed During Childhood

Background: Most children with primary immune deficiency (PID) now reach adulthood. However, few studies have evaluated their health status and health related quality of life (HRQoL).

Objective: To investigate long-term morbidity, the French Reference Center for PIDs initiated a prospective multicenter cohort: the F-CILC (French Childhood Immune deficiency Long-term Cohort). The data collected will be used to assess the physical health condition of patients who reached adulthood and the impact on their quality of life.

Methods: Patients are asked to complete health status questionnaires. A severity score (grade1 \["mild"\] to grade 4 \["life-threatening"\]) is assigned to each health condition. The HRQoL of patients is compared to age- and sex-matched French normal values using the SF36 HRQoL questionnaire.

Capsule summary. This will be the first study of adult survivors of childhood PID describing how the burden of health conditions affect their quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Patient with primary immune deficiency diagnosed during childhood

Exclusion Criteria:

* Patients not willing to answer to quality of life questionnaires
Dermacyd Infantile (Lactic Acid)- Compatibility.

Primary Objective:

To demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergic potential (sensibilization) of the product Dermacyd Infantile.


Eligibility Criteria:
Inclusion criteria:

* Photo type Skin I,II, III e IV
* Integral skin test in the region
* Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion.

Exclusion criteria:

* Lactation or gestation
* Use of Anti-inflammatory 30 days and/or immunosuppressant drugs during 3 months before the selection
* Diseases which can cause immunity decrease, such as HIV, diabetes
* Previous atopy
* History of sensitivity or irritation for topic products
* Active cutaneous diseases which can interfere in the study results
* Use of new drugs and/ or cosmetics during the study
* Cutaneous reactivity
* Previous participation in studies, which had used the product
* Volunteers who have immunodeficiency congenital or acquired
* Relevant clinical history or present evidence of alcohol abuse or others drugs
* Non tolerance to some component of the study product.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Effectiveness of an Intensive Intervention to Improve Physical Activity in Postmenopausal and Sedentary Women

This is a randomized clinical trial aimed at postmenopausal women aged 45 to 70 years old selected in urban primary care centers of two centers (Spain). Its objective is to evaluate the effects of an intensive intervention in the increase of physical activity and the decrease of sedentary lifestyle in postmenopausal and sedentary women.

Objective: to evaluate the effects at 6 months of an intensive intervention in the increase of physical activity and the decrease of sedentary lifestyle in postmenopausal and sedentary women.

Design and setting: A randomized clinical trial of two parallel groups. Population: 100 postmenopausal women, 45 to 70 aged will be included, selected by consecutive sampling in two primary care centers.

Measurements and intervention: Physical activity, body composition, BMI and health-related quality of life will be evaluated. The intervention group will receive an intensive program of combined exercise for 6 months and use during this period a Smartband, in order to encourage and increase physical activity and decrease sedentary lifestyle

Eligibility Criteria:
Inclusion Criteria:

* Women in postmenopausal period defined as 12 consecutive months of amenorrhea.

Exclusion Criteria:

* Older than 70 years are excluded, due to difficulties in the use of Information and Communication Technologies.
* History of cardiovascular events (acute myocardial infarction, stroke, etc).
* Diagnosis of clinically demonstrable neurological and/or neuropsychological disease.
* Muscular-skeletal pathology that inhibit mobility.
* Those with any other circumstance that the investigators consider could interfere with the study procedures.
Diaphragm Pacing in Individuals With Spinal Cord Injuries

This project will evaluate the effects of intramuscular diaphragm stimulation (pacing) and test the hypothesis that diaphragm pacing enhances neuromuscular diaphragm activation and respiratory function in adults with cervical spinal cord injuries (C-SCIs). The investigators will test the hypothesis by recording activity of the diaphragm from intramuscular pacing electrodes and conduct respiratory assessments in adults with intramuscular diaphragm pacing electrodes following acute, traumatic C-SCIs.

Respiratory dysfunction is a leading cause of death in individuals with spinal cord injuries (SCIs). Nearly one-quarter of all SCI cases involve injury to the upper spinal cord segments which impairs neural activation of the diaphragm muscle and compromises breathing. Although mechanical ventilation can be life-saving after cervical SCI (C-SCI), it also triggers rapid and profound diaphragm muscle atrophy, thereby complicating (or even preventing) ventilator weaning. Intramuscular diaphragm stimulation, or diaphragm pacing, was developed to replace long-term ventilator support and is now used acutely post C-SCI (\<4 months following injury) to promote ventilator weaning. This study will assess the effects of diaphragm stimulation on respiratory neural drive and breathing function in individuals with acute, traumatic C-SCI. Recording from these surgically implanted electrodes allows comparisons of electromyogram (EMG) recordings, in association with respiratory assessments, before and after short periods of diaphragm pacing to isolate the unique contribution of diaphragm pacing on neuromuscular diaphragm activation.

Eligibility Criteria:
Inclusion Criteria:

* Acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C
* Scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation

Exclusion Criteria:

* Progressive neuromuscular diseases such as multiple sclerosis and myasthenia gravis
* History of neurologic injuries such as stroke or prior SCI
* Chest wall injuries or deformities likely to influence breathing
* Pregnancy
* Cognitive impairments limiting study participation
Expanding Donor Pool for Live Donor Liver Transplantation: Utilization of Donors With NASH After Optimization

Live donor liver transplantation (LDLT) is the treatment of choice for end-stage liver disease, predominantly in the East, where deceased donor liver transplantation is sparse. In LDLT, donor selection has to be stringent; as the donor safety is thepriority. Live liver donors (LLD) with complex biliary and vascular anatomy are increasingly being accepted for donation with the betterment of technical expertise. One of the commonest reasons for LLD rejection is the hepatic parenchymal abnormality because ofsteatosis and steatohepatitis, which can increase the donor risk. Retrospective analysis of donors with non-alcoholic steatohepatitis(NASH) who were optimized and taken up for major hepatectomy from June 2011 to January 2018will be performed.

Study Design Aim and Objective -

* Primary objective:
* To study the effect of donor optimization protocol in donors with biopsy proven NASH
* To study thebiochemical (LFTSs \& INR) recovery in donors with NASH after major hepatectomy
* To compare their biochemical recovery parameters (LFTs \& INR) with that of non NASH donors.
* Secondary objectives:
* To study incidence of NASH among live liver donors
* To study their respective recipients' outcomes
* To study the morbidity among LLDs with NASH after major hepatectomy

Methodology:

* Study population:Patients underwentLDLT from June 2011 to January 2019 at Institute of Liver \& Biliary Sciences, New Delhi
* Study design:Retrospective study
* Study period:from June 2011 to January 2019
* Sample size with justification:All consecutive LLDs with at least one year of follow up post-operatively
* Intervention: none
* Monitoring and assessment:none Statistical Analysis:Categorical variables were presented as number (percentage) and were compared using the Chi-square test. Continuous variables were presented as mean (standard deviation, SD) and were compared using Mann-Whitney U Test.

Adverse Effects: None Stopping Rule of Study: None

Expected Outcome of the Project: Adherence to a strict dietary and lifestyle modifications plan will cause histological reversal of NASH and fibrosis in LLDs. Their clinical and biochemical recovery following the major hepatectomy will be similar to that of non-NASH LLDs.

Eligibility Criteria:
Inclusion Criteria:

1. Live Liver Donors who had undergone major hepatectomy (removal of ≥ 3 liver segments)

Exclusion Criteria:

1. Live Liver Donors who had undergone minor hepatectomy (removal of \< 3 liver segments)
2. Live Liver Donors of recipients with acute liver failure.
Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin

The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema.

A blind study and a randomized and controlled clinical trial are conducted on diabetic patients with macular edema. The patients are divided into two intervention groups (bevacizumab + curcumin) and control (bevacizumab + placebo).

The evaluation of the central thickness of the macula and the evaluation of the central volume of the macula are the primary goals and the evaluation of the best visual acuity of the patient is the secondary goal.


Eligibility Criteria:
Inclusion Criteria:

Patients with center-involving macular edema with macular center thickness more than 300 microns in OCT 2-Patients who did not receive intravitreal bevacizumab in the last 3 months and intravitreal corticosteroids in the last 6 months.

3- The amount of BCVA should not be \<20/400. 4-Consent to participate in the study

Exclusion Criteria:

1. Other retinal diseases except for DME and macular edema due to other causes including uveitis, epiretinal membrane, central retinal vein occlusion, and...
2. Existence of proliferative diabetic retinopathy and patients with a history of vitrectomy
3. Patients with glaucoma, vitreous hemorrhage, age-related macular degeneration (ARMD)
4. Media opacities that limit the interpretation of diagnostic tests
5. Surgery or procedure 3 months before starting treatment
6. Pregnancy or breastfeeding
7. History of allergy to curcumin
8. Use of warfarin
9. Changing the patient's clinical diagnosis or the need for surgical interventions in the course of the disease
10. Change in the patient's general health condition
11. Absence of patient referrals
12. Lack of consent to continue treatment and follow-up
To Investigate the Role of Upstream High Dose Statin in STEMI

This is a double-blinded randomized placebo controlled trial investigating the role of upstream 80mg Atorvastastin-calcium in patients undergoing percutaneous intervention for acute STEMI.


Eligibility Criteria:
Inclusion Criteria:

1. Any patient of 25 to 90 years of age admitted or transferred to Western Pennsylvania Hospital or Allegheny General Hospital with a diagnosis of STEMI undergoing emergent percutaneous intervention (PCI) to the culprit coronary artery. STEMI is defined as greater than 1mm ST segment elevation on electrocardiogram.
2. Elevated cardiac biomarkers (troponin-T \> 0.03ng/ml, CKMB\>5ng/mL, or ck\>170 U/l).

Exclusion Criteria:

1. Known history of liver disease defined as cirrhosis, alcoholic liver disease, Non alcoholic steatohepatitis, hepatitis or any causes of liver failure.
2. Renal failure with creatinine \>3mg/dL
3. Known history of liver or muscle disease such as rheumatologic myopathies, history of myositis, hepatitis, and hepatic cancer.
4. Cardiovascular arrest and shock.